(Q37579647)

21 August 2017

1 reference

title

Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer (English)

1 reference

21 August 2017

1 reference

1 reference

3

1 reference

21 August 2017

F R Hirsch

1

1 reference

PubMed ID

19680294

21 August 2017

M Varella-Garcia

series ordinal

2

1 reference

PubMed ID

19680294

21 August 2017

language of work or name

English

0 references

publication date

1 August 2009

1 reference

21 August 2017

1 reference

21 August 2017

28 Suppl 1

1 reference

21 August 2017

S32-7

1 reference

https://scigraph.springernature.com/pub.10.1038/onc.2009.199

21 August 2017

0 references

cites work

Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.199

Signaling through the epidermal growth factor receptor during the development of malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.199

HER2/neu expression in malignant lung tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.199

Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.199

Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.199

Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.199

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.199

The role of EGF-R expression on patient survival in lung cancer: a systematic review with meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.199

Analysis of c-ErbB1/epidermal growth factor receptor and c-ErbB2/HER-2 expression in bronchial dysplasia: evaluation of potential targets for chemoprevention of lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.199

Synchronous overexpression of epidermal growth factor receptor and HER2-neu protein is a predictor of poor outcome in patients with stage I non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.199

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.199

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.199

Safety and efficacy of darbepoetin alpha in previously untreated extensive-stage small-cell lung cancer treated with platinum plus etoposide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.199

Quantitative immunohistochemical analysis of transforming growth factor-alpha and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.199

Epidermal growth factor-related peptides and their receptors in human malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.199

Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.199

Erlotinib in lung cancer - molecular and clinical predictors of outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.199

Structural alterations of the epidermal growth factor receptor gene in human gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.199

Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.199

Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.199

Prospective Study of Gefitinib in Epidermal Growth Factor Receptor Fluorescence In Situ Hybridization–Positive/Phospho-Akt–Positive or Never Smoker Patients With Advanced Non–Small-Cell Lung Cancer: The ONCOBELL Trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.199

Predicting gefitinib responsiveness in lung cancer by fluorescence in situ hybridization/chromogenic in situ hybridization analysis of EGFR and HER2 in biopsy and cytology specimens

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.199

Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.199

Retinoic acid normalizes the increased gene transcription rate of TGF-alpha and EGFR in head and neck cancer cell lines

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.199

Impact of HER2 and EGFR gene status on gefitinib-treated patients with nonsmall-cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.199

31 March 2020

Identifiers

DOI

10.1038/ONC.2009.199

1 reference

21 August 2017

1 reference

PubMed ID

19680294